Impact of special patient populations on the pharmacokinetics of echinocandins

References

• Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014;10:95-105
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54(8):1110-22
   PubMed Web of Science ®Google Scholar
• Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25(7):419-25
   PubMed Web of Science ®Google Scholar
• Benjamin DKJr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117(1):84-92
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012;18(Suppl 7):53-67
   PubMed Web of Science ®Google Scholar
• Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18(Suppl 7):38-52
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15(8):e327-40
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011;46(5):709-18
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Cancidas; summary of product characteristics. 28-09-2011. Available from: www.ema.europa.eu/humandocs/Humans/EPAR/cancidas/cancidas.htm [Last accessed on 10-2011]
   Google Scholar
• EMA. Mycamine; summary of product characteristics. 14-09-2011. Available from: www.emea.europa.eu/humandocs/Humans/EPAR/mycamine/mycamine.htm [Last accessed on 09-2012]
   Google Scholar
• EMA. Ecalta; summary of product characteristics. 15-10-2009. Available from: www.ema.europa.eu/humandocs/Humans/EPAR/ecalta/ecalta.htm [Last accessed on 12-2009]
   Google Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71(1):11-41
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006;45(11):1077-97
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14(6):498-509
   PubMed Web of Science ®Google Scholar
• Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012;51(5):277-304
   PubMed Web of Science ®Google Scholar
• Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012;18(5):460-71
   PubMed Web of Science ®Google Scholar
• Andes D, Ambrose PG, Hammel JP, et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother 2011;55(5):2113-21
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, et al. In vivo Comparison of the Pharmacodynamic Target Among Echinocandin Drugs and Candida species. Antimicrob.Agents Chemother 2010;54(6):2497-506
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197(1):163-71
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ecalta: EPAR - Scientific Discussion 2007. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000788/WC500020673.pdf [Last accessed on 10-2014]
   Google Scholar
• Rajman I, Desante K, Hatcher B, et al. LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers. In: 37th Interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology; 1997 [Abstract F-74]
   Google Scholar
• Bruggemann RJ, Van Der Velden WJ, Knibbe CA, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48(6):2021-4
   PubMed Web of Science ®Google Scholar
• Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans by degradation not metabolism. Clin Microbiol Infect 2003;9(Suppl 1s):291
   Google Scholar
• Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005;45(2):227-33
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45(12):1373-82
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007;47(3):305-14
   PubMed Web of Science ®Google Scholar
• Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48(10):1441-58
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44(6):590-8
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46(3):739-45
   PubMed Web of Science ®Google Scholar
• Migoya E, Mistry GC, Stone JA, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol 2011;51(2):202-11
   PubMed Web of Science ®Google Scholar
• Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000;28(11):1274-8
   PubMed Web of Science ®Google Scholar
• Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004;48(3):815-23
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005;33(5):676-82
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez C, Arranz R, Cisneros JM, et al. Absence of clinically relevant effect of caspofungin on cyclosporine pharmacokinetics. Swiss Med Wkly 2005;135(43-44):658-9
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008;27(1):1-6
   PubMed Web of Science ®Google Scholar
• Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48(11):4306-14
   PubMed Web of Science ®Google Scholar
• Krishna G, Vickery D, Ma L, et al. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. J Clin Pharmacol 2011;51(1):84-92
   PubMed Web of Science ®Google Scholar
• Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48(12):1676-84
   PubMed Web of Science ®Google Scholar
• European medicines agency. Assessment report for Mycamine. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000734/WC500031079.pdf [Last accessed on 2008;10-2014]
   Google Scholar
• Sakaeda T, Iwaki K, Kakumoto M, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005;57(6):759-64
   PubMed Web of Science ®Google Scholar
• Fukuoka N, Imataki O, Ohnishi H, et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2010;42(7):2725-30
   PubMed Web of Science ®Google Scholar
• Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45(9):1018-24
   PubMed Web of Science ®Google Scholar
• Inoue Y, Saito T, Ogawa K, et al. Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 2012;50(11):831-7
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-6
   PubMed Web of Science ®Google Scholar
• Keirns J, Sawamoto T, Holum M, et al. Steady-state pharmacokinetics (PK) of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob.Agents Chemother 2007;51(2):787-90
   PubMed Web of Science ®Google Scholar
• Undre NA, Stevenson P, Wilbraham D. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects. Int J Clin Pharmacol Ther 2014;52(3):237-44
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349(12):1157-67
   PubMed Web of Science ®Google Scholar
• Admiraal R, van Kesteren C, Boelens JJ, et al. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 2014;99(3):267-72
   PubMed Web of Science ®Google Scholar
• Ince I, Knibbe CA, Danhof M, de Wildt SN. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet 2013;52(5):333-45
   PubMed Web of Science ®Google Scholar
• Benjamin DK. Jr., Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112(3 Pt 1):634-40
   PubMed Web of Science ®Google Scholar
• Autmizguine J, Guptill JT, Cohen-Wolkowiez M, et al. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs 2014;74(8):891-909
   PubMed Web of Science ®Google Scholar
• Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet 2014;53(5):429-54
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Benjamin DKJr, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011;89(5):702-7
   PubMed Web of Science ®Google Scholar
• Benjamin DKJr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53(3):869-75
   PubMed Web of Science ®Google Scholar
• Jans J, Bruggemann RJ, Christmann V, et al. Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin. Antimicrob Agents Chemother 2013;57(5):2391-3
   PubMed Web of Science ®Google Scholar
• Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009;53(4):1450-6
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49(11):4536-45
   PubMed Web of Science ®Google Scholar
• Li CC, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother 2011;55(5):2098-105
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25(12):1110-15
   PubMed Web of Science ®Google Scholar
• Benjamin DKJr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87(1):93-9
   PubMed Web of Science ®Google Scholar
• Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J 2009;28(9):840-2
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28(5):412-15
   PubMed Web of Science ®Google Scholar
• Yanni SB, Smith PB, Benjamin DKJr, et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos 2011;32(4):222-32
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49(8):3317-24
   PubMed Web of Science ®Google Scholar
• Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull 2006;29(8):1706-11
   PubMed Web of Science ®Google Scholar
• Albano E, Azie N, Roy M, et al. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2015;37(1):e45-50
   PubMed Web of Science ®Google Scholar
• Undre NA, Stevenson P, Freire A, Arrieta A. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 2012;31(6):630-2
   PubMed Web of Science ®Google Scholar
• Benjamin DKJr, Deville JG, Azie N, et al. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J 2013;32(11):e419-25
   PubMed Web of Science ®Google Scholar
• Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007;51(10):3714-19
   PubMed Web of Science ®Google Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77-89
   PubMed Web of Science ®Google Scholar
• Knibbe CA, Brill MJ, van Rongen A, et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 2015;55:149-67
   PubMed Web of Science ®Google Scholar
• Liu P. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob Agents Chemother 2013;57(1):466-74
   PubMed Web of Science ®Google Scholar
• Liu P, Ruhnke M, Meersseman W, et al. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrob Agents Chemother 2013;57(4):1672-6
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007;60(1):100-6
   PubMed Web of Science ®Google Scholar
• Muilwijk EW, Schouten JA, van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 2014;69(12):3294-9
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Young C, Lanvers-Kaminsky C, et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2012;56(1):536-43
   PubMed Web of Science ®Google Scholar
• Hall RG2nd, Swancutt MA, Meek C, et al. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother 2013;57(5):2259-64
   PubMed Web of Science ®Google Scholar
• Gumbo T, Hiemenz J, Ma L, et al. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008;60(3):329-31
   PubMed Web of Science ®Google Scholar
• Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2011;55(11):5107-12
   PubMed Web of Science ®Google Scholar
• Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005;45(10):1145-52
   PubMed Web of Science ®Google Scholar
• Pasipanodya J, Hall R2nd, Gumbo T. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clin Pharmacol Ther 2015;97(3):292-7
   PubMed Web of Science ®Google Scholar
• Zomp A, Bookstaver PB, Ahmed Y, et al. Micafungin therapy in a critically ill, morbidly obese patient. J Antimicrob Chemother 2011;66(11):2678-80
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64(12):1147-61
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007;47(4):461-70
   PubMed Web of Science ®Google Scholar
• Aguilar G, Azanza JR, Sadaba B, et al. Pharmacokinetics of anidulafungin during albumin dialysis. Crit Care 2014;18(2):422
   PubMed Web of Science ®Google Scholar
• Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 2007;47(8):951-61
   PubMed Web of Science ®Google Scholar
• Spriet I, Meersseman W, Annaert P, et al. Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis. Eur J Clin Pharmacol 2011;67(7):753-5
   PubMed Web of Science ®Google Scholar
• van der Elst KC, Bruggemann RJ, Rodgers MG, Alffenaar JW. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transpl Infect Dis 2012;14(4):440-3
   PubMed Web of Science ®Google Scholar
• Spriet I, Meyfroidt G, Maleux G, et al. The impact of a transjugular intrahepatic portosystemic shunt on the pharmacokinetics of caspofungin in a critically ill patient. Pharmacology 2012;90(5-6):247-50
   PubMed Web of Science ®Google Scholar
• Neely M, Blumer J. Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients. Curr Ther Res Clin Exp 2003;64(2):127-36
   PubMed Web of Science ®Google Scholar
• Undre N, Pretorius B, Stevenson P. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction. Eur J Drug Metab Pharmacokinet 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kishino S, Ohno K, Shimamura T, Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004;18(6):676-80
   PubMed Web of Science ®Google Scholar
• Muraki Y, Iwamoto T, Kagawa Y, et al. The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction. Biol Pharm Bull 2009;32(4):750-4
   PubMed Web of Science ®Google Scholar
• Mochizuki N, Matsumoto K, Ohno K, et al. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant Proc 2006;38(10):3649-50
   PubMed Web of Science ®Google Scholar
• Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol 2011;4(2):261-74
   PubMedGoogle Scholar
• Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009;34(3):282-3
   PubMed Web of Science ®Google Scholar
• Aguilar G, Azanza JR, Carbonell JA, et al. Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. J Antimicrob Chemother 2014;69(6):1620-3
   PubMed Web of Science ®Google Scholar
• Leitner JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother 2011;66(4):880-4
   PubMed Web of Science ®Google Scholar
• Honore PM, Jacobs R, De Waele E, Spapen HD. Anidulafungin dosing during CRRT: do not underestimate adsorption!. Crit Care 2014;18:618
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Cancidas : EPAR - scientific discussion. 2005; Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000379/human_med_000684.jsp&mid=WC0b01ac058001d124 [ [Last accessed on 10-2011]
   Google Scholar
• Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 2013;57(8):4053-7
   PubMed Web of Science ®Google Scholar
• Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007;127(5):897-901
   PubMed Web of Science ®Google Scholar
• Maseda E, Grau S, Villagran MJ, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother 2014;69(6):1624-32
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50(2):99-110
   PubMed Web of Science ®Google Scholar
• Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009;63(4):767-70
   PubMed Web of Science ®Google Scholar
• Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47(10):635-54
   PubMed Web of Science ®Google Scholar
• van Wanrooy MJ, Rodgers MG, Uges DR, et al. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother 2014;58(1):304-8
   PubMed Web of Science ®Google Scholar
• Ruiz S, Papy E, Da Silva D, et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 2009;35(1):183-4
   PubMed Web of Science ®Google Scholar
• Jullien V, Blanchet B, Benyamina M, et al. Pharmacokinetics of caspofungin in two patients with burn injuries. Antimicrob Agents Chemother 2012;56(8):4550-1
   PubMed Web of Science ®Google Scholar
• Sasaki J, Yamanouchi S, Kudo D, et al. Micafungin concentrations in the plasma and burn eschar of severely burned patients. Antimicrob Agents Chemother 2012;56(2):1113-15
   PubMed Web of Science ®Google Scholar
• Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother 2014;58(8):4718-26
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 2011;55(12):5798-803
   PubMed Web of Science ®Google Scholar
• Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010;54(10):4143-9
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Cornely OA, Trame MN, et al. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother 2013;57(4):1664-71
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Kako S, et al. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2013;15(3):323-7
   PubMed Web of Science ®Google Scholar
• Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect 2014;68(Suppl 1)):S24-32
   Google Scholar
• Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007;3(4):573-81
   PubMed Web of Science ®Google Scholar
• Fungal Pharmacology. Available from: www.fungalpharmacology.org/
   Google Scholar
• Ullmann AJ, Cornely OA, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012;18(Suppl 7):1-8
   PubMed Web of Science ®Google Scholar
• Undre N, Stevenson P, Kuse ER, Demeyer I. Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Open J Med Microbiol 2012;2:84-90
   Google Scholar